What's Happening?
Bionova Scientific has opened a new facility in Texas, located less than 50 km north of Houston, to design, develop, and manufacture research-grade plasmid DNA (pDNA) materials. This expansion is aimed at supporting the cell and gene therapy field, which is experiencing rapid growth. The facility will enable Bionova to offer clinical to commercial-scale Current Good Manufacturing Practice (CGMP) production of pDNA by the fourth quarter of 2025. Plasmid DNA is crucial for mRNA and viral vector-based therapies, and Bionova's new capabilities are intended to meet the persistent unmet needs within the biopharma community. The company is part of Asahi Kasei’s Life Science group and is expanding its presence to align with the evolving needs of the biopharmaceutical industry.
AD
Why It's Important?
The opening of Bionova Scientific's new facility in Texas is significant for the biopharmaceutical industry, particularly in the cell and gene therapy sector. As the global pharmaceutical market is projected to reach nearly $3 trillion by 2033, the demand for advanced therapy development and manufacturing is increasing. Bionova's expansion into pDNA production addresses a critical need for reliable and timely support in the biopharma community, potentially accelerating the development of next-generation therapies. This move also strengthens Bionova's position in the rapidly expanding cell and gene therapy ecosystem in the U.S., fostering partnerships that could drive innovation and growth in the industry.
What's Next?
Bionova Scientific plans to begin CGMP production of pDNA by Q4 2025, which will further enhance its service offerings. The company aims to build lasting partnerships within the cell and gene therapy sector, leveraging its new capabilities to support emerging therapy developers. As part of Asahi Kasei’s medium-term growth plan, Bionova will continue to invest in specialized capabilities, including virus filtration and CRO testing, to meet the evolving demands of the biopharmaceutical industry.
